| 000 | 01892 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518013028.0 | ||
| 264 | 0 | _c20191008 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1097-0215 | ||
| 024 | 7 |
_a10.1002/ijc.32058 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Lindi | |
| 245 | 0 | 0 |
_aPreclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. _h[electronic resource] |
| 260 |
_bInternational journal of cancer _c06 2019 |
||
| 300 |
_a3146-3159 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNeuroblastoma _xdrug therapy |
| 650 | 0 | 4 |
_aProdrugs _xpharmacokinetics |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-mdm2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrrolidines _xpharmacokinetics |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 |
_aTemozolomide _xadministration & dosage |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xgenetics |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 650 | 0 | 4 |
_apara-Aminobenzoates _xpharmacokinetics |
| 700 | 1 | _aPastorino, Fabio | |
| 700 | 1 | _aBerry, Philip | |
| 700 | 1 | _aBonner, Jennifer | |
| 700 | 1 | _aKirk, Calum | |
| 700 | 1 | _aWood, Katrina M | |
| 700 | 1 | _aThomas, Huw D | |
| 700 | 1 | _aZhao, Yan | |
| 700 | 1 | _aDaga, Antonio | |
| 700 | 1 | _aVeal, Gareth J | |
| 700 | 1 | _aLunec, John | |
| 700 | 1 | _aNewell, David R | |
| 700 | 1 | _aPonzoni, Mirco | |
| 700 | 1 | _aTweddle, Deborah A | |
| 773 | 0 |
_tInternational journal of cancer _gvol. 144 _gno. 12 _gp. 3146-3159 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ijc.32058 _zAvailable from publisher's website |
| 999 |
_c29150080 _d29150080 |
||